WO2003014728A1 - Medicaments contre l'hepatite c - Google Patents
Medicaments contre l'hepatite c Download PDFInfo
- Publication number
- WO2003014728A1 WO2003014728A1 PCT/JP2002/008175 JP0208175W WO03014728A1 WO 2003014728 A1 WO2003014728 A1 WO 2003014728A1 JP 0208175 W JP0208175 W JP 0208175W WO 03014728 A1 WO03014728 A1 WO 03014728A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hepatitis
- protein
- virus
- antibody
- absence
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 3
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003519409A JP4221292B2 (ja) | 2001-08-10 | 2002-08-09 | C型肝炎治療薬 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001243947 | 2001-08-10 | ||
JP2001-243947 | 2001-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003014728A1 true WO2003014728A1 (fr) | 2003-02-20 |
Family
ID=19073953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/008175 WO2003014728A1 (fr) | 2001-08-10 | 2002-08-09 | Medicaments contre l'hepatite c |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4221292B2 (fr) |
WO (1) | WO2003014728A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006057339A1 (fr) * | 2004-11-25 | 2006-06-01 | Mitsubishi Pharma Corporation | Procede de production d'anticorps |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018198A1 (fr) * | 1997-10-06 | 1999-04-15 | Chiron S.P.A. | Proteine receptrice cd81 de l'hepatite c |
-
2002
- 2002-08-09 JP JP2003519409A patent/JP4221292B2/ja not_active Expired - Fee Related
- 2002-08-09 WO PCT/JP2002/008175 patent/WO2003014728A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018198A1 (fr) * | 1997-10-06 | 1999-04-15 | Chiron S.P.A. | Proteine receptrice cd81 de l'hepatite c |
Non-Patent Citations (3)
Title |
---|
ALLANDER TOBIAS ET AL.: "Recombinant human monoclobal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81", vol. 81, no. 10, October 2000 (2000-10-01), pages 2451 - 2459, XP002939743 * |
PILERI P. ET AL.: "Binding of hepatitic C virus to CD81", SCIENCE, vol. 282, 30 October 1998 (1998-10-30), pages 938 - 941, XP002092549 * |
SHU KIKUCHI ET AL.: "Ketsueki baikai kansensho HCV", RINSHO TO KENKYU, vol. 76, no. 7, 1999, pages 1260 - 1266, XP002961752 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006057339A1 (fr) * | 2004-11-25 | 2006-06-01 | Mitsubishi Pharma Corporation | Procede de production d'anticorps |
Also Published As
Publication number | Publication date |
---|---|
JPWO2003014728A1 (ja) | 2004-11-25 |
JP4221292B2 (ja) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993000365A3 (fr) | Polypeptides utilises dans la lutte contre le virus de l'hepatite c | |
ID21649A (id) | Inhibitor serum protease, terutama virus hepatitis c ns3 protease | |
GB2365429B (en) | Improvements to ribosome display | |
AU5285899A (en) | Anti hepatitis c virus antibody and uses thereof | |
WO2002057293A3 (fr) | Protéines de liaison en doigt de gant modifiées | |
WO2001081421A3 (fr) | Peptides de synthese qui se fixent au coeur du virus de l'hepatite b et aux antigenes e | |
WO2003002749A3 (fr) | Procedes servant a detecter simultanement des antigenes de hcv et des anticorps anti-hcv | |
WO1992017493A3 (fr) | Peptides et melanges de peptides servant a detecter les anticorps diriges contre le virus de l'hepatite c | |
EP1305438A4 (fr) | Particules de type virus ameliorees fondees sur une petite proteine d'enveloppe provenant de l'hepatite b (aghbs) | |
PT698216E (pt) | Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes | |
AU2001232267A1 (en) | Remedies for hepatitis c | |
EP1111385A3 (fr) | Complexe d'une enzyme et une protéine | |
WO2003087138A3 (fr) | Procedes d'identification de facteurs polypeptidiques ayant une interaction avec l'arn | |
WO2002062959A3 (fr) | Traitement du virus de l'hepatite b | |
WO1996035717A3 (fr) | Substrats clivables, solubles, de la protease du virus de l'hepatite c | |
WO2002060954A8 (fr) | Materiaux et procedes destines au traitement de l'hepatite c | |
WO2001017537A3 (fr) | Techniques et compositions permettant de reduire la reponse immunitaire | |
WO2002055560A3 (fr) | Anticorps monoclonaux specifiques a la glycoproteine e2 du virus de l'hepatite c et leurs utilisations dans le diagnostic, le traitement et la prevention de l'hepatite c | |
WO2003014728A1 (fr) | Medicaments contre l'hepatite c | |
ATE472337T1 (de) | Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung | |
WO2004021871A3 (fr) | Dosage biologique dans le cas du virus de l'hepatite c | |
WO2003040341A3 (fr) | Anticorps contre le virus de l'hepatite a | |
EP0516859A4 (fr) | ||
AU8405798A (en) | A swine hepatitis e virus and uses thereof | |
AU2002257890A1 (en) | Method for replicating the hepatitis C virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003519409 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |